EUCTR2004-001546-32-FI进行中（未招募）不适用
A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy
ovartis Finland Oy0 个研究点目标入组 345 人开始时间: 2004年7月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes, previously treated with a sulfonylurea for at least 3 months, aged 18-80 years, body mass index of 22-45 kg/m2, HbA1c 7.5-11% inclusive, FPG < 270 mg/dL (15 mmol/L) and agreement to maintain prior diet and exercise.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a history of type 1 diabetes, diabetes that is a result of pancreatic injury or secondary forms of diabetes, acute metabolic diabetic complications within past 6 months; evidence of significant diabetic complications; acute infections which may affect blood glucose control within the past 4 weeks; Torsades de Pointes, ventricular tachycardia, ventricular fibrillation; percutaneous coronary intervention in the past 3 months; myocardial infarction, coronary artery bypass surgery, or unstable angina within the past 6 months; congestive heart failure NYHA class III or IV; second degree AV block (Mobitz 1 and 2), third degree AV block, prolonged QTc; malignancy including leukemia and lymphoma within the last 5 years; liver disease; acromegaly or treatment with growth hormone; known sensitivity to glimepiride; treatment with any oral antidiabetic other than sulfonylureas within the past 3 months; chronic insulin treatment within the past 6 months; chronic oral or parenteral corticosteroid treatment within the past 8 weeks; treatment with class Ia, Ib, Ic, or III anti-arrhythmics; significant laboratory abnormalities.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg or to amlodipine 5 mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5 mg once daily - NDEUCTR2007-004726-24-ITOVARTIS FARMA670
进行中（未招募）
不适用
A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once dailyEUCTR2007-004726-24-SKovartis Pharma Services AG670
进行中（未招募）
不适用
A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once dailyEssential HypertensionEUCTR2007-004726-24-HUovartis Pharma Services AG670
进行中（未招募）
不适用
A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once dailyEssential HypertensionEUCTR2007-004726-24-SEovartis Pharma Services AG670
进行中（未招募）
不适用
A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once dailyEssential HypertensionMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2007-004726-24-FIovartis Pharma Services AG670